Clinical bottom line
Early use of intravenous liposomal bupivacaine in emergency department (ED) surgical patients is a putative strategy to improve postoperative pain control while potentially reducing opioid requirements. Emerging evidence, primarily from elective surgical settings, suggests that liposomal bupivacaine provides prolonged analgesia compared to standard bupivacaine formulations. However, direct data on intravenous administration in the ED context remain limited. This candidate approach warrants cautious consideration and further validation before routine adoption in emergency postoperative pain management.
What the evidence shows
Liposomal bupivacaine is a sustained-release formulation designed to extend local anesthetic effects up to 72 hours post-administration. Most clinical data derive from perioperative infiltration or regional blocks rather than intravenous use. For example, Pan et al. (2026) demonstrated that continuous bupivacaine infusion was non-inferior to liposomal bupivacaine in parasacral ischial plane blocks after total knee arthroplasty, indicating comparable analgesic efficacy in a controlled setting. Similarly, studies in orthopedic surgery have shown reduced postoperative opioid consumption and improved pain scores with liposomal bupivacaine infiltration compared to standard bupivacaine (OrthoEvidence, 2019; Hamilton et al., 2014).
Uyere et al. (2023) investigated liposomal bupivacaine’s impact on postoperative pain management with a focus on opioid use disorder risk reduction, highlighting its potential to decrease opioid exposure in acute care. Additionally, Aslam et al. (2023) reported enhanced recovery in laparoscopic colorectal cancer surgery patients using combined liposomal bupivacaine fascial plane infiltration and short-acting spinal anesthesia, suggesting multimodal benefits.
However, these studies predominantly involve local or regional administration rather than intravenous delivery. The pharmacokinetics, safety, and efficacy of intravenous liposomal bupivacaine remain underexplored. Intravenous acetaminophen has been more extensively studied for postoperative pain but differs mechanistically and pharmacologically (Kumar et al., 2014).
Caveats and uncertainty
The evidence supporting intravenous liposomal bupivacaine in the ED postoperative setting is currently indirect and extrapolated from elective surgical populations and local/regional administration routes. There is a lack of randomized controlled trials specifically evaluating intravenous liposomal bupivacaine in emergency surgical patients, who often have more variable clinical presentations and comorbidities.
Safety concerns include potential systemic toxicity, altered pharmacodynamics in critically ill or polypharmacy patients, and unknown interactions with other emergency medications. The cost-effectiveness and logistical feasibility of intravenous liposomal bupivacaine in the fast-paced ED environment also remain unaddressed.
Furthermore, the heterogeneity in surgical procedures, pain severity, and patient factors in emergency settings complicates generalizability. Existing studies often have small sample sizes and limited follow-up durations, restricting conclusions about long-term outcomes and opioid-sparing effects.
How this may change practice
If validated, early intravenous liposomal bupivacaine could become a valuable adjunct in multimodal postoperative pain management protocols in the ED, potentially reducing opioid reliance and improving patient comfort. Emergency clinicians might consider integrating this agent selectively for patients undergoing surgical interventions with anticipated moderate to severe pain.
However, until robust, ED-specific evidence emerges, clinicians should remain cautious and prioritize established analgesic regimens supported by current guidelines. Participation in clinical trials or registries evaluating intravenous liposomal bupivacaine in emergency postoperative care is encouraged to build the evidence base.